What is the difference between Nivestym and Neupogen?
Medically reviewed by Drugs.com. Last updated on Sep 11, 2023.
Nivestym (filgrastim-aafi) is a biosimilar to Neupogen,
A biosimilar is a biological product that is highly similar to a biologic already approved by the FDA (known as the reference product, in this case Neupogen) and has no clinically meaningful differences in terms of safety, purity and potency from the reference product. Biosimilars can provide cost effective treatment options to already approved biologics.
Nivestym cannot be interchanged with Neupogen at the pharmacy level; the physician must specifically order Nivestym.
Nivestym (filgrastim-aafi) is a recombinant human granulocyte colony-stimulating factor biosimilar to Neupogen indicated for the treatment of neutropenia associated with chemotherapy and related conditions.
Nivestym is used for the same indications as Neupogen.
Learn More: What Are Biosimilars? Top Facts You May Not Know
Read next
Related medical questions
- What biosimilars have been approved in the United States?
- New 'Biosimilars' may help Reduce Medication Costs
- Why do you take Claritin with Neulasta?
- How long do the side effects of the Neulasta (pegfilgrastim) shot last?
- Does Neulasta cause bone pain?
- When does Neulasta reach peak levels?
- Can you shower with Neulasta on body injector?
- How is Fulphila injected / administered?
- Is Fulphila a chemo drug?
- What is the difference between Udenyca and Fulphila?
Drug information
Related support groups
- Nivestym (3 questions, 4 members)
- Filgrastim (3 questions, 5 members)
- Neupogen (3 questions, 16 members)
- Neutropenia Associated with Chemotherapy (12 questions, 5 members)
- Neutropenia (1 questions, 15 members)
